Evidence map›Paper›PMID 29104624›Full record

ArticleExperimental and therapeutic medicine2017

Smart watch-based coaching with tiotropium and olodaterol ameliorates physical activity in patients with chronic obstructive pulmonary disease.

Osamu Hataji, Yoichi Nishii, Kentaro Ito, Tadashi Sakaguchi, Haruko Saiki, Yuta Suzuki, Corina D'Alessandro-Gabazza, Hajime Fujimoto, Tetsu Kobayashi, Esteban C Gabazza and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Osamu HatajiRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie 515-8544, Japan.
Yoichi NishiiRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie 515-8544, Japan.
Kentaro ItoRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie 515-8544, Japan.
Tadashi SakaguchiRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie 515-8544, Japan.
Haruko SaikiRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie 515-8544, Japan.
Yuta SuzukiRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie 515-8544, Japan.
Corina D'Alessandro-GabazzaDepartment of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
Hajime FujimotoDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
Tetsu KobayashiDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
Esteban C GabazzaDepartment of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
Osamu TaguchiMental and Physical Health Center, Mie University Faculty and Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
Soka Municipal Hospital · JPMie University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combined therapy with tiotropium and olodaterol notably improves parameters of lung function and quality of life in patients with chronic obstructive pulmonary disease (COPD) compared to mono-components; however, its effect on physical activity is unknown. The present study evaluated whether combination therapy affects daily physical performance in patients with COPD under a smart watch-based encouragement program. This was a non-blinded clinical trial with no randomization or placebo control. A total of 20 patients with COPD were enrolled in the present study. The patients carried an accelerometer for 4 weeks; they received no therapy during the first 2 weeks but they were treated with combined tiotropium and olodaterol under a smart watch-based encouragement program for the last 2 weeks. The pulmonary function test, COPD assessment test, 6-min walk distance and parameters of physical activity were significantly improved (P<0.05) by combination therapy under smart watch-based coaching compared with values prior to treatment. To the best of our knowledge, the present study for the first time provides evidence that smart watch-based coaching in combination with tiotropium and olodaterol may improve daily physical activity in chronic obstructive pulmonary disease.

Indexed as

chronic obstructive pulmonary diseaselong-acting muscarinic antagonistlong-acting β2-agonistphysical activitysmart watch

Identifiers

PMID29104624
PMCPMC5658686
OpenAlexW2751454816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.